Skip to main content

King’s People

Dr Christine Galustian

Academics

Group leader (non-clinical) Prostate Cancer Immunotherapy group

Senior Fellow.

Contact details

Biography

Christine is a PI and Non-clinical lead of the Prostate Cancer Immunotherapy group which holds a Centre grant from the Prostate Cancer Research Centre at King's. Christine has a team of 4 scientists that are developing novel immunotherapeutic agents for prostate cancer and are testing these compounds in-vitro and in pre-clinical models.

The group has a translational approach to guide novel immunotherapeutics from the lab to the patient, where Christine is linked to the clinical lead Professor Dasgupta, who is planning clinical trials on the therapeutics produced in the lab along with Dr Richard Smith who directs the chemical synthesis and development of therapeutics through his novel cytotopic technology

Latest publications

Prostate cancer cells enhance interleukin-15-mediated expansion of NK cells
Sakellariou, C., Elhage, O., Papaevangelou, E., Giustarini, G., Da Silva Esteves, A. M. E., Smolarek, D., Smith, R., Dasgupta, P. & Galustian, C., 7 Aug 2019, In : BJU International. 125, 1, p. 89-102 14 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1111/bju.14893
Mutation of duffy antigen receptor for chemokines (DARC) as an indicator of prostate cancer severity in Afro-Caribbean men
Galustian, C., Rani, A., Cahill, F., Santaolalla, A., Gillett, C., Lombardelli, C., Rosekilly, J., Sakellariou, C., George, G., Papaevangelou, E., Smith, R., Smolarek, D., Van Hemelrijck, M. & Dasgupta, P., 24 Mar 2017, In : EUROPEAN UROLOGY SUPPLEMENTS. 16, 3, p. e622-e623 Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1016/s1569-9056(17)30419-0
REGULATION OF THE CCL2-CCR2 AXIS THROUGH THE JAK-STAT PATHWAY AND ROLE IN CANCER METASTASIS
Rani, A., Murphy, J. & Galustian, C., Nov 2016, In : Cytokine. 87, p. 59-+ Research output: Contribution to journal - Article
Immune checkpoint blockade - a treatment for urological cancers?
Elhage, O., Galustian, C. & Dasgupta, P., Oct 2016, In : BJU International. 118, 4, p. 498-500 3 p. Research output: Contribution to journal - Comment/debate. DOIs: https://doi.org/10.1111/bju.13571
Cathepsin-L and Transglutaminase Dependent Processing of ps20: A novel Mechanism for ps20 Regulation via ECM Cross-Linking
Hickman, O. J., Dasgupta, P., Galustian, C., Smith, R. A. & Vyakarnam, A., Sep 2016, In : Biochemistry and Biophysics Reports . 7, p. 328-337 10 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1016/j.bbrep.2016.06.010
Expression of two WFDC1/ps20 isoforms in prostate stromal cells induces paracrine apoptosis through regulation of PTGS2/COX-2
Hickman, O. J., Smith, R., Dasgupta, P., Rao, S. N., Nayak, S., Sreenivasan, S., Vyakarnam, A. & Galustian, C., 26 Apr 2016, In : British Journal of Cancer. p. 1-8 8 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1038/bjc.2016.91
Regulatory T cells
Galustian, C. & Dasgupta, P., 15 Apr 2016, In : The Encyclopedia of Life Sciences. Research output: Contribution to journal - Literature review. DOIs: https://doi.org/10.1002/9780470015902.a0004029.pub3
HES1 in immunity and cancer
Rani, A., Greenlaw, R., Smith, R. A. & Galustian, C., 19 Mar 2016, In : Cytokine and Growth Factor Reviews. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1016/j.cytogfr.2016.03.010
The Notch target HES1, is a STAT5 target gene which could have implications in cancer therapeutics
Rani, A., Galustian, C. & Murphy, J., Nov 2015, In : Cytokine. 76, 1, p. 103-103 Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1016/j.cyto.2015.08.214
Extending the lifespan and efficacies of immune cells used in adoptive transfer for Cancer immunotherapies: a review
Nayar, S., Dasgupta, P. & Galustian, C., 2015, In : OncoImmunology. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1080/2162402X.2014.1002720

View all publications